- 1 Middle meningeal artery embolization for subdural hematoma:
- 2 protocol for a systematic review and meta-analysis of randomized
- 3 controlled trials
- 4 Alick P Wang\*<sup>1</sup> MD MSc, Husain Shakil<sup>2</sup> MD MSc, Brian J Drake<sup>1</sup> MBBCh MPH FRCSC
- 5 1. Division of Neurosurgery, Department of Surgery, University of Ottawa
- 6 2. Division of Neurosurgery, Department of Surgery, University of Toronto
- 7 \* Corresponding author:
- 8 Alick P Wang, MD MSc
- 9 The Ottawa Hospital, Civic Campus
- 10 1053 Carling Ave, Ottawa Ontario, Canada, K1Y4E9
- 11 alickwang@gmail.com

### **Abstract**

13 (178 words)

12

- 14 Background: Middle meningeal artery embolization is an emerging neuroendovascular therapy
- 15 for chronic subdural hematoma. Recently, a number of randomized control trials have been
- 16 conducted to assess the efficacy of middle meningeal artery embolization to reduce the
- 17 recurrence or progression of chronic subdural hematoma.
- Methods: A systematic review will be conducted following the Preferred Reporting Items for
- 19 Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The authors will systematically
- search MEDLINE, EMBASE, Cochrane, and ClinicalTrials.gov (National Library of Medicine)
- 21 for randomized control trials evaluating middle meningeal artery embolization for chronic
- subdural hematoma. A meta-analysis will be undertaken to compare patients undergoing middle
- 23 meningeal artery embolization and standard care compared to standard care alone; primary
- 24 effectiveness endpoints will be symptomatic recurrence, radiographic re-accumulation, or
- 25 reoperation; secondary safety endpoints will be new disabling stroke, myocardial infarction, or
- death within 30 days.
- 27 Discussion: This proposed systematic review and meta-analysis will synthesize and appraise
- 28 available data regarding middle meningeal artery embolization, a novel neurointerventional
- 29 therapy. Findings will help clinicians, patients, administrators, policy makers to determine the
- 30 role of this new treatment and its potential benefits.
- 31 Systematic review registration: PROSPERO #CRD42024512049

## 32 **Keywords**

- 33 Meta-analysis; Middle meningeal artery embolization; Randomized control trial; Subdural
- 34 hematoma.

## **Background**

- 36 Chronic subdural hematoma (CSDH) is a common condition, with an incidence of up to 20.6 per
- 37 100,000 person-years<sup>1</sup>. It disproportionately affects elderly populations and is often caused by
- 38 minor trauma. It can cause symptoms ranging from headaches to confusion, decreased level of
- 39 consciousness, weakness, aphasia, or seizures.
- Depending on the volume, local mass effect, and symptoms, chronic SDH has been treated either
- 41 surgically (burr hole evacuation, craniotomy, or subdural drainage ports) or conservatively
- 42 (medical therapy or observation/serial imaging). Conservatively managed SDH can progress in
- 43 up to 34% of cases<sup>2</sup>. After surgical evacuation, recurrence rates have been estimated between 10-
- 44  $20\%^3$ .

- 45 Recently, endovascular embolization of the middle meningeal artery (EMMA) has become an
- emerging therapy for CSDH<sup>4</sup>. While EMMA was initially used in patients who were at high risk
- 47 of recurrence, the indications have recently widened to all patients with CSDH. Although
- 48 EMMA does not immediately remove the SDH or its mass effect, it is hypothesized to
- 49 devascularize the subdural membrane and prevent recurrence or progression.
- 50 EMMA has been used in cases of small, asymptomatic SDH not requiring surgery<sup>5</sup> as well as in
- cases of SDH requiring surgical evacuation<sup>6</sup>. A recent systematic review found that EMMA
- reduced the risk of recurrence from 23.5% to 3.5% (RR 0.17)<sup>7</sup>. However, at the time of
- publication, there had not been any prospectively conducted randomized control trials (RCTs).
- Recently, a number of multi-centre RCTs have been conducted to evaluate the efficacy of
- 55 EMMA for reducing recurrence or progression in CSDH. A meta-analysis of these trials has yet
- to be performed.

### Methods/Design

- This protocol outlines the design and conduct of our intended systematic review and meta-
- analysis in compliance with the guideline Preferred Reporting Items for Systematic Reviews and
- 60 Meta-analyses (PRISMA). The protocol has been submitted to the PROSPERO database and
- assigned the unique identifier #CRD42024512049. This study was exempt from institutional
- research ethics board review under article 1B of the University of Toronto policy on Human
- Research Exempt from REB Review (https://research.utoronto.ca/ethics-human-
- 64 research/activities-exempt-human-ethics-review)

#### 65 Study Aim

- We aim to conduct a meta-analysis of available data from RCTs comparing the efficacy of
- 67 EMMA in addition to standard of care to standard of care alone. The primary efficacy endpoints
- will be the likelihood of SDH recurrence, re-accumulation, or re-operation at 90 days, and 180
- 69 days.

57

#### 70 Data Sources and Study Eligibility

- 71 Two authors (APW, HS) will independently search citations from MEDLINE, EMBASE,
- 72 Cochrane, and ClinicalTrials.gov (National Library of Medicine) without language restriction
- 73 (see Appendix 1 for search strategy). We will include randomized control trials studying adult
- 74 patients (≥ 18 years of age) with radiographic diagnosis of chronic or subacute SDH, with at
- 75 least 10 patients, and at least 90 days of follow-up.

#### 76 Treatment Groups

- 77 The intervention group of interest will be the use of EMMA in addition to standard of care. The
- 78 control group will be treatment with standard of care alone. Standard of care will include
- 79 observation, medical therapy, burr hole, mini-craniotomy, craniotomy, and subdural evacuation
- 80 port system.

#### 81 *Outcomes*

- 82 The primary effectiveness endpoints for this study will be symptomatic recurrence, radiographic
- re-accumulation, or reoperation at 90, and 180 days. We will also aim to assess a secondary
- 84 safety endpoint of new major disabling stroke, myocardial infarction, or death from any
- 85 neurological cause within 30 days.

#### Data Extraction

86

- 87 Spreadsheet software will be used by two authors (APW, HS) to extract study design,
- 88 inclusion/exclusion criteria, randomization characteristics, patient population, primary and
- 89 secondary outcome measures, and sources of bias, and covariates. Covariates will include age,
- 90 standard treatment approach used, presence of symptoms, type of embolization material, and use
- 91 of general anesthetic for EMMA procedure.

#### 92 Risk of Bias/Quality Assessment

- Two reviewers (APW, HS) will independently perform quality assessment of included studies.
- The Cochrane ROB 2 tool<sup>8</sup> will be applied to assess the risk of bias related to the randomization
- 95 process, deviations from intended interventions, missing data, measurement of the outcome, and
- selection of the reported results. We judged trials with more than 2 high-risk components as
- 97 having a moderate overall risk of bias, and trials with more than 4 high-risk components as
- having a high overall risk of bias. The GRADE approach will be used for appraisal of the
- 99 quality of evidence.

### Statistical Analysis

- All analyses will be conducted in R version 4.3.1 with a priori specified significance level of p <
- 102 0.05 for two-tailed tests. We will follow an intention-to-treat approach in assigning treatment
- 103 groups.

- The odds ratio (OR) of SDH recurrence and associated 95% confidence intervals (CI) for
- 105 EMMA with standard therapy compared to standard therapy alone will be estimated for each
- study using logistic regression.
- 107 Heterogeneity in the treatment effect across trials will be investigated by the Cochran Q test and
- measured by the  $I^2$  statistic, with  $I^2$  values exceeding 25%, 50%, and 75% representing low,
- moderate, and high heterogeneity, respectively<sup>10</sup>. Treatment effect estimates will be pooled using
- a fixed effect Mantel-Haenszel method if heterogeneity is found to be low heterogeneity. A
- DerSimonian and Laird random-effects model<sup>11</sup> will be used if moderate-high heterogeneity is
- 112 found.
- Publication bias will be assessed using Funnel plots and Egger's test<sup>12</sup>. We will further
- investigate the effect of covariates including age, standard treatment approach, presence of
- symptoms, history of prior subdural hematoma, use of general anesthetic, and type of
- embolization material used. We will assess missingness of covariates and outcomes. Based on
- data availability, we will conduct subgroup analyses based on presence of symptoms, type of
- standard management (e.g. conservative, medical, burr-hole, and craniotomy), older patients, or
- patients with prior subdural hematoma. We will not impute data on outcomes or treatment
- assignment, and will only analyze available data for these variables. For study covariates, we
- will impute data found to be missing completely at random, or missing at random there is less
- than 20% missingness.

**Discussion** 123 124 This proposed systematic review and meta-analysis will address an important knowledge gap regarding EMMA, a novel neurointerventional therapy. 125 While several studies have evaluated the safety and benefit of EMMA<sup>3</sup>, up until recently there 126 had not been any prospective RCTs conducted to evaluate its efficacy. Recently, a number of 127 multi-centre RCTs have been completed and early results have been presented at the 128 International Stroke Conference 2024. 129 130 A meta-analysis of RCTs will help clinicians, patients, administrators, policy makers to

determine the role of this new treatment and its potential benefits.

# List of abbreviations

- 133 CSDH chronic subdural hematoma
- 134 EMMA embolization of the middle meningeal artery
- 135 MMA middle meningeal artery
- 136 PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses
- 137 RCT randomized control trial
- 138 SDH subdural hematoma

**Declarations** 139 140 Ethics approval 141 No ethics approval required for systematic review. Availability of data and materials 142 All data will be extracted from publicly available publications. Extracted data will be made 143 144 available upon reasonable request. 145 Competing interests 146 No competing interests to declare. 147 **Funding** No funding to declare. 148 149 Authors' contributions

APW, HS, and BJD study conception. APW and HS protocol design and drafting.

### References

- 152 1. Feghali, J., Yang, W. & Huang, J. Updates in Chronic Subdural Hematoma: Epidemiology, Etiology, Pathogenesis, Treatment, and Outcome. World Neurosurg 141, 339–345 (2020).
- Foppen, M., Bandral, H. V., Slot, K.-A. M., Vandertop, W. P. & Verbaan, D. Success of conservative therapy for chronic subdural hematoma patients: a systematic review.
  Frontiers in Neurology 14, (2023).
- Almenawer, S. A. et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg 259, 449–457 (2014).
- Rudy, R. F., Catapano, J. S., Jadhav, A. P., Albuquerque, F. C. & Ducruet, A. F. Middle
  Meningeal Artery Embolization to Treat Chronic Subdural Hematoma. Stroke: Vascular
  and Interventional Neurology 3, e000490 (2023).
- Rojas-Villabona, A. et al. A systematic review of middle meningeal artery embolization for minimally symptomatic chronic subdural haematomas that do not require immediate evacuation. Brain and Spine 3, 102672 (2023).
- Lam, A. et al. The efficacy of postoperative middle meningeal artery embolization on
  chronic subdural hematoma A multicentered randomized controlled trial. Surg Neurol Int
  14, 168 (2023).
- Dian, J., Linton, J. & Shankar, J. J. Risk of recurrence of subdural hematoma after EMMA
  vs surgical drainage Systematic review and meta-analysis. Interv Neuroradiol 27, 577–
  583 (2021).
- Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.
  BMJ 366, 14898 (2019).
- 9. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924–926 (2008).
- 175 10. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557–560 (2003).
- 177 11. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177–178 188 (1986).
- 179 12. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 (1997).

# **Appendix 1:**

182 Search Strategy

- The following search strategy will be employed for the MEDLINE database using the OVID
- interface.

- 185 1. exp Hematoma, Subdural/
- 186 2. exp Embolization Therapeutic/
- 187 3. exp Meningeal Arteries/
- 4. exp Endovascular Procedures/
- 189 5. Exp Clinical Trial/
- 190 6. 2 or 3 or 4
- 191 7. 1 and 5 and 6